Selection of Candidates for Lung Transplantation and Controversial Issues

Abstract

Lung transplantation is a widely accepted treatment to manage the advanced stages of many lung diseases that have failed to respond to all other therapeutic interventions. There have been ever-expanding indications for lung transplantation as a treatment for lung disease. The International Society for Heart and Lung Transplantation (ISHLT) updated guidelines for candidate selection in 2014. This document was published to serve as a guide in selecting appropriate candidates for lung transplantation. Ideal candidates for lung transplantation are those with near-end stage disease, limited life expectancy due to their lung disease, and who experience significant loss in quality of life. At the same time, candidates should be free of significant comorbidities that might negatively impact successful transplantation. Despite well thought out published guidelines for candidate selection, many controversial issues surrounding selection of lung transplant candidates remain. This review will focus on some of the more common controversial issues and explain how most centers approach these issues when choosing candidates for lung transplantation.

Keywords

lung transplantation - indications - candidate selection

• References

• 1 Weill D, Benden C, Corris PA. , et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34 (01) 1-15
• 2 Reitz BA, Wallwork JL, Hunt SA. , et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306 (10) 557-564
• 3 Chambers DC, Yusen RD, Cherikh WS. , et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017; 36 (10) 1047-1059
• 4 Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. J Heart Lung Transplant 1998; 17 (07) 703-709
• 5 Orens JB, Estenne M, Arcasoy S. , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update–a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (07) 745-755
• 6 Egan TM, Bennett LE, Garrity ER. , et al. Predictors of death on the UNOS lung transplant waiting list: results of a multivariate analysis. J Heart Lung Transplant 2001; 20 (02) 242
• 7 Egan TM, Murray S, Bustami RT. , et al. Development of the new lung allocation system in the United States. Am J Transplant 2006; 6 (5 Pt 2): 1212-1227
• 8 Carr G, Garrity ER. Lung transplantation outcome changes from the new US lung allocation system. Clin Pulm Med 2012; 19: 39-43
• 9 Mason DP, Thuita L, Nowicki ER, Murthy SC, Pettersson GB, Blackstone EH. Should lung transplantation be performed for patients on mechanical respiratory support? The US experience. J Thorac Cardiovasc Surg 2010; 139 (03) 765-773.e1
• 10 Valapour M, Skeans MA, Smith JM. , et al. OPTN/SRTR 2015 Annual Data Report: lung. Am J Transplant 2017; 17 (Suppl. 01) 357-424
• 11 Biscotti M, Gannon WD, Agerstrand C. , et al. Awake extracorporeal membrane oxygenation as bridge to lung transplantation: a 9-year experience. Ann Thorac Surg 2017; 104 (02) 412-419
• 12 Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998; 351 (9095): 24-27
• 13 Celli BR, Cote CG, Marin JM. , et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350 (10) 1005-1012
• 14 Thabut G, Ravaud P, Christie JD. , et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177 (10) 1156-1163
• 15 Anthonisen NR. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989; 140 (3 Pt 2): S95-S99
• 16 Connors Jr AF, Dawson NV, Thomas C. , et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154 (4 Pt 1): 959-967
• 17 Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167 (04) 544-549
• 18 Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. ; Greater Manchester Pulmonary Fibrosis Consortium. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001; 164 (01) 103-108
• 19 Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 2014; 14: 139
• 20 Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155 (05) 1699-1704
• 21 Dobbin C, Maley M, Harkness J. , et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004; 56 (04) 277-282
• 22 Chaparro C, Maurer J, Gutierrez C. , et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163 (01) 43-48
• 23 Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164 (11) 2102-2106
• 24 Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis 2014; 16 (04) 578-587
• 25 Parize P, Boussaud V, Poinsignon V. , et al. Clinical outcome of cystic fibrosis patients colonized by Scedosporium species following lung transplantation: a single-center 15-year experience. Transpl Infect Dis 2017;19(5)
• 26 Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326 (18) 1187-1191
• 27 Liou TG, Adler FR, Cox DR, Cahill BC. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007; 357 (21) 2143-2152
• 28 D'Alonzo GE, Barst RJ, Ayres SM. , et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115 (05) 343-349
• 29 Badesch DB, Tapson VF, McGoon MD. , et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132 (06) 425-434
• 30 Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123 (02) 344-350
• 31 Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15 (1 Pt 1): 100-105
• 32 Zapol WM, Snider MT, Hill JD. , et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 1979; 242 (20) 2193-2196
• 33 Fuehner T, Kuehn C, Hadem J. , et al. Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. Am J Respir Crit Care Med 2012; 185 (07) 763-768
• 34 Mohite PN, Rosenberg A, Caballero CH. , et al. Escalation of extracorporeal life support as a bridge to lung transplantation in end-stage lung disease. Perfusion 2017; 32 (07) 606-608
• 35 Kilic A, Merlo CA, Conte JV, Shah AS. Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score?. J Thorac Cardiovasc Surg 2012; 144 (05) 1133-1138
• 36 Weiss ES, Merlo CA, Shah AS. Impact of advanced age in lung transplantation: an analysis of United Network for Organ Sharing data. J Am Coll Surg 2009; 208 (03) 400-409
• 37 Shoham S, Shah PD. Impact of multidrug-resistant organisms on patients considered for lung transplantation. Infect Dis Clin North Am 2013; 27 (02) 343-358
• 38 Nash EF, Coonar A, Kremer R. , et al. Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis. Transpl Infect Dis 2010; 12 (06) 551-554
• 39 Lobo LJ, Tulu Z, Aris RM, Noone PG. Pan-resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia infection in cystic fibrosis does not reduce survival after lung transplantation. Transplantation 2015; 99 (10) 2196-2202
• 40 Olivier KN, Weber DJ, Wallace Jr RJ. , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167 (06) 828-834
• 41 Knoll BM, Kappagoda S, Gill RR. , et al. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis 2012; 14 (05) 452-460
• 42 Chalermskulrat W, Sood N, Neuringer IP. , et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61 (06) 507-513
• 43 Gilljam M, Scherstén H, Silverborn M, Jönsson B, Ericsson Hollsing A. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010; 9 (04) 272-276
• 44 Lobo LJ, Chang LC, Esther Jr CR, Gilligan PH, Tulu Z, Noone PG. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 2013; 27 (04) 523-529
• 45 Magruder JT, Crawford TC, Grimm JC. , et al. Risk factors for de novo malignancy following lung transplantation. Am J Transplant 2017; 17 (01) 227-238
• 46 Engels EA, Pfeiffer RM, Fraumeni Jr JF. , et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306 (17) 1891-1901
• 47 Garver Jr RI, Zorn GL, Wu X, McGiffin DC, Young Jr KR, Pinkard NB. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999; 340 (14) 1071-1074
• 48 Ahmad U, Wang Z, Bryant AS. , et al. Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry. Ann Thorac Surg 2012; 94 (03) 935-940 , discussion 940–941
• 49 Schachna L, Medsger Jr TA, Dauber JH. , et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54 (12) 3954-3961
• 50 Khan IY, Singer LG, de Perrot M. , et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013; 107 (12) 2081-2087
• 51 Crespo MM, Bermudez CA, Dew MA. , et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann Am Thorac Soc 2016; 13 (06) 784-792
• 52 Miele CH, Schwab K, Saggar R. , et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction. A comprehensive single-center experience. Ann Am Thorac Soc 2016; 13 (06) 793-802